Cargando…

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban

Background: Atrial fibrillation (AF) is the most common arrhythmia associated with high risk of venous thromboembolism. Inflammatory mechanisms may be involved in the pathophysiology of AF and in the AF-related thrombogenesis, and patients with AF might benefit from the use of anticoagulants with an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martins, Gabriela Lopes, Duarte, Rita Carolina Figueiredo, Vieira, Érica Leandro Marciano, Rocha, Natalia Pessoa, Figueiredo, Estêvão Lanna, Silveira, Francisco Rezende, Caiaffa, José Raymundo Sollero, Lanna, Rodrigo Pinheiro, Carvalho, Maria das Graças, Palotás, András, Ferreira, Cláudia Natália, Reis, Helton José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393940/ https://www.ncbi.nlm.nih.gov/pubmed/32793635 http://dx.doi.org/10.3389/fcvm.2020.00114

Ejemplares similares

Evaluation of New Potential Inflammatory Markers in Patients with Nonvalvular Atrial Fibrillation
por: Martins, Gabriela Lopes, et al.
Publicado: (2023)

Troponina – Use com Sabedoria. E como mais um Instrumento na Clínica
por: Wang, Ricardo, et al.
Publicado: (2022)

Efeitos Anti-inflamatórios e Cardioprotetores do HDL-C: Associação com Autoanticorpos contra LDL Oxidada?
por: Figueiredo, Estêvão Lanna, et al.
Publicado: (2022)

Inflammatory and Infectious Processes Serve as Links between Atrial Fibrillation and Alzheimer’s Disease
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Tópicos Emergentes em Insuficiência Cardíaca: Nova Era do Tratamento Farmacológico
por: Marcondes-Braga, Fabiana G., et al.
Publicado: (2020)

Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations
por: Duarte, Rita Carolina Figueiredo, et al.
Publicado: (2017)

Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease
por: Martins, Gabriela L., et al.
Publicado: (2023)

Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease
por: Figueiredo, Estêvão Lanna, et al.
Publicado: (2015)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
por: Stolz, Leonie, et al.
Publicado: (2017)

Rivaroxaban versus warfarin for the management of left ventricle thrombus
por: Albabtain, Monirah A., et al.
Publicado: (2021)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain
por: Tito, Pedro Augusto Lopes, et al.
Publicado: (2021)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
por: Sherid, Muhammed, et al.
Publicado: (2016)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Neuroinflammation and Neurodegeneration: Pinpointing Pathological and Pharmacological Targets
por: de Oliveira, Antonio Carlos Pinheiro, et al.
Publicado: (2015)

Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease
por: Rocha, Natália Pessoa, et al.
Publicado: (2014)

Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
por: Durães, André R., et al.
Publicado: (2018)

Warfarin and Rivaroxaban Duplication: A Case Report and Medication Error Analysis
por: Fusco, Julie A., et al.
Publicado: (2015)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency
por: Ameku, Koken, et al.
Publicado: (2018)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke
Publicado: (2010)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Evo-devo of non-bilaterian animals
por: Lanna, Emilio
Publicado: (2015)

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects
por: Kubitza, Dagmar, et al.
Publicado: (2014)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
por: Kleintjens, Joris, et al.
Publicado: (2013)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8frthlk9no8edjgc3d0bd348fe